Irritable Bowel Syndrome News

Reports of sensitization to cat dander were found to be higher among patients with IBS, which may explain the high prevalence of asthma in this population, according to data presented at the AGA’s 2015 James W. Freston Conference in Chicago.

For patients with refractory diarrhea-predominant irritable bowel syndrome, nutritional management with serum-derived bovine immunoglobulin/protein isolate, a prescription medical food, effectively improved their symptoms, according to data presented at the AGA’s 2015 James W. Freston Conference in Chicago.

Data from a randomized controlled trial presented at the AGA’s 2015 James W. Freston Conference in Chicago, showed a novel emotional awareness and expression training intervention improved IBS symptoms, distress and quality of life as effectively as relaxation training.

IBgard LPB, a new, more purified formulation of IBgard, an over-the-counter medical food containing a blend of L-menthol and peppermint oil, improved IBS symptoms within 4 weeks, according to data presented at the AGA’s 2015 James W. Freston Conference in Chicago.

According to a recent systematic review, elimination diets cannot be strongly recommended to patients with irritable bowel syndrome until further evidence becomes available.

Low FODMAP diet reduced abdominal pain frequency in children with irritable bowel syndrome, and those who responded had different baseline gut microbial composition, according to study results.

Data supporting the low FODMAP diet for the treatment of irritable bowel syndrome is “very limited,” and caution should be used when recommending it to patients, according to a recently published review.

Health Canada’s Natural and Non-Prescription Health Products Directorate has approved an efficacy supplement that increases the speed of action of IBgard, an over-the-counter treatment for irritable bowel syndrome, the manufacturer announced.

Ironwood Pharmaceuticals today announced it has entered into an agreement with Allergan to co-promote Viberzi, a recently approved drug for diarrhea-predominant irritable bowel syndrome in adults, according to a press release.

Commonwealth Laboratories has announced its agreement with Valeant Pharmaceuticals for the latter to acquire the former’s U.S. and Canadian business, including the rights to IBSchek, a new blood test for irritable bowel syndrome.